Table of Content
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Neurological Diseases
4.2.2 Rising Awareness for Early Disease Diagnosis
4.2.3 Increasing Number of Research and Development for Neurological Diseases
4.3 Market Restraints
4.3.1 High Cost for Diagnosis and Treatment
4.3.2 Stringent Regulations Associated with the Neurological Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Disorders
5.1.1 Epilepsy
5.1.2 Alzheimer’s Disease
5.1.3 Parkinson’s Disease
5.1.4 Multiple Sclerosis
5.1.5 Cerebrovascular Disease
5.1.6 Other Disorders
5.2 By Drug Type
5.2.1 Cholinesterase Inhibitors
5.2.2 NMDA Receptor Antagonists
5.2.3 Antiepileptic
5.2.4 Antipsychotic and Antidepressant
5.2.5 Other Drugs Type
5.3 By Distribution Channels
5.3.1 Hospital Pharmacies
5.3.2 Online Pharmacies
5.3.3 Retail Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co.,Inc
6.1.2 AstraZeneca
6.1.3 Abbott
6.1.4 F. Hoffmann-La Roche Ltd.
6.1.5 Novartis AG
6.1.6 Pfizer Inc.
6.1.7 Sanofi
6.1.8 Bayer AG
6.1.9 Johnson & Johnson Private Limited
6.1.10 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS